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Moderate intensity aerobic exercise training or regular physical activity is beneﬁcial for immune function. For example, some
evidence shows that individuals with an active lifestyle exhibit stronger immune responses to vaccination compared to those who
are inactive. Encouragingly, poor vaccine responses, which are characteristic of an ageing immune system, can be improved by
single or repeated bouts of exercise. In addition, exercise-induced lymphocytosis, and the subsequent lymphocytopenia, is thought
to facilitate immune surveillance, whereby lymphocytes search tissues for antigens derived from viruses, bacteria, or malignant
transformation. Aerobic exercise training is anti-inﬂammatory and is linked to lower morbidity and mortality from diseases with
infectious, immunological, and inﬂammatory aetiologies, including cancer. These observations have led to the view that aerobic
exercise training might counter the age-associated decline in immune function, referred to as immunosenescence. This article
summarises the aspects of immune function that are sensitive to exercise-induced change, highlighting the observations which
have stimulated the idea that aerobic exercise training could prevent, limit, or delay immunosenescence, perhaps even restoring
aged immune proﬁles. These potential exercise-induced anti-immunosenescence eﬀects might contribute to the mechanisms by
which active lifestyles reduce the risk of developing cancer and perhaps beneﬁt patients undergoing cancer therapy.
1. Introduction and Overview
Since the ﬁrst observations of the immune system being
modulated by bouts of vigorous exercise in the 1890s, a sub-
stantial body of evidence has accumulated showing that most
aspects of immune function are sensitive to exercise-induced
change [1]. Many of these changes have been interpreted as
being beneﬁcial, and this view has led to aerobic exercise
training being advocated as a method to prevent, limit, or
delay the age-associated decline in immune function referred
to as immunosenescence [2–4]. It has even been suggested
that aerobic exercise training might rejuvenate aged immune
proﬁles [2, 3], which is attractive given our ageing popula-
tion, and the potential implications that immunosenescence
has for increasing susceptibility to infections and increasing
the risk of developing cancer.
The purpose of this article is to summarise the eﬀects
that aerobic exercise training and physical activity can have
on aspects of immune function with an emphasis on how
some of these changes could be considered as countering
immunosenescence. Few studies have investigated changes
to immune function brought about resistance exercise (e.g.,
lifting weights) or high-intensity sprint interval exercise;
therefore, these activities will remain largely undiscussed.
In addition, this article will summarise studies that have
investigated whether immunosenescence inﬂuences the risk
of developing cancer or aﬀects the treatment of patients with
a cancer diagnosis. Readers are directed towards articles that
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have reviewed these concepts in more depth, including the
eﬀects of exercise on immune function [1, 5, 6], the inﬂu-
ence of chronological age and infection history on immu-
nosenescence [7–9], the eﬀects of aerobic exercise training
on immunosenescence [2–4, 10], and the links between
immunosenescence and cancer risk or treatment [11–13].
2. Characteristics of an Ageing Immune System
The proﬁle of the innate and adaptive immune system is
markedly diﬀerent between young and elderly individuals.
For example, with ageing, there is an increase in systemic
inﬂammatory activity referred to as inﬂammageing [14, 15].
Age-associated alterations are also observed with the num-
ber, phenotype, and function of innate immune cells [9].
Neutrophils exhibit diminished phagocytosis and have an
impaired capacity to control their direction of migration
(chemotaxis), but their speed of movement (chemokinesis)
is maintained. Mast cells decline in number but not function,
whereas the number of eosinophils and basophils, along
with their function, remains largely unchanged. Monocyte
numbers in peripheral blood are stable with ageing, but
classical cells (CD14++CD16−) decline, and intermediate
(CD14+CD16+) and nonclassical (CD14+CD16++) cells
increase [9, 16]. These numerical changes coincide with
altered signalling via some toll-like receptors resulting in
impaired cytokine production. Changes in monocytes due
to age per se are thought to be mirrored by the phenotype
and functional properties of tissue macrophages, whereby
classically activated M1 cells decline and alternatively acti-
vated M2 cells accumulate [17]. However, the composition
of tissue-resident cells is complicated by adipose tissue accu-
mulation and dysfunction—dominated by M1 macrophages
[18, 19]—and the M1/M2 paradigm is likely to be an over-
simpliﬁcation [20, 21]. It is unclear if ageing aﬀects the num-
ber of dendritic cells in peripheral blood, but numbers
decline in the skin and mucosal membranes, and antigen
processing and presentation, cytokine production, costimu-
latory capacity, and migration are impaired. The number of
natural killer cells increases with ageing, but this change var-
ies by subtype; cytotoxic cells accumulate and regulatory cells
decline; however, overall cytokine production and cytotoxic-
ity are less on a per cell basis. With ageing, there is a decline
in the number of invariant natural killer T cells (iNKT
cells)—innate lymphocytes, which represent <1% of the T
cell pool and recognise tumours or infected cells via
CD1d-presented glycolipids [22]. It is possible that some of
these age-associated changes are driven by an increase in
myeloid-derived suppressor cells (MDSCs)—a heterogenous
population of granulocytes, macrophages, and dendritic cells
that suppress aspects of immune function by producing
reactive oxygen species and inhibitory cytokines [23].
Within the adaptive immune system, a classical hallmark
of ageing that predicts mortality in the elderly is impaired
mitogen-induced T cell proliferation [24]. Many other age-
associated changes to T cell numbers and phenotypes have
been reported. For example, among T cell subpopulations,
such as CD4+ T-helper (Th) cells, ageing is associated with
a predominance of cells with a Th2 cytokine proﬁle (i.e., IL-
4 and IL-10 producing cells), whereas there is a decline in
cells with a Th1 proﬁle (i.e., IFN-γ and TNF-α producing
cells) [25]. Another functional shift in T-helper cell proﬁle
includes an accumulation of IL-17 producing cells that are
associated with autoimmunity and inﬂammatory disease
[26]. Other characteristic observations among T cells include
decreased numbers and proportions of CD4+ and CD8+
naïve T cells and increased numbers and proportions of
late-stage diﬀerentiated eﬀector memory CD4+ and CD8+
T cells [7, 8]. These changes are largely driven by a combina-
tion of three factors: ﬁrst, lower numbers of haematopoietic
stem cells which also exhibit intrinsic damage and a pheno-
type skewed towards the myeloid lineage; second, thymic
involution and reduced output of antigen-naïve T cells; and
third, infection with latent herpes viruses, in particular, Cyto-
megalovirus (CMV) [7, 27]. Among the less abundant T cell
populations, natural regulatory T cells (nTREGs) increase
with ageing whereas inducible TREGs decrease [28]. It is
unclear whether the suppressive capability of these cells is
altered with ageing: an increase could promote immune sup-
pression and cancer, whereas a decrease could promote
immune activation and autoimmunity [28]. T cells that
express natural killer cell-associated cell-surface proteins
(NKT-like cells) increase with ageing and exhibit similar
changes to their phenotype, functional properties, and spec-
iﬁcities as with the broader populations of CD4+ and CD8+
T cells [22]. With ageing, there is a decline in the number
of γδ T cells; however, age per se, in the absence of chronic
infections, is associated with a decline in Vδ2 cells (60–80%
of γδ T cells), whereas Vδ1 (15–20% γδ T cells) remain
stable [29]. As with T cells, ageing is associated with a
decline in the numbers and proportions of naïve B cells,
an accumulation of memory B cells with limited speciﬁc-
ities, and less robust antibody production by plasma cells
in response to novel antigens [30]. Some of these parame-
ters, when clustered together, have been shown to predict
all-cause mortality in studies of octogenarians and nonage-
narians [31, 32]. These characteristics, which were referred
to as the Immune Risk Proﬁle (IRP), included low numbers
and proportions of B cells, high numbers and proportions
of late-stage diﬀerentiated CD8+ T cells, poor T cell prolif-
eration in response to mitogens, and a ratio of CD4+ T
cells to CD8+ T cells less than 1.0 [31, 32]. Infection with
CMV was part of the IRP [33], and later work showed
that plasma IL-6 was associated with frailty, cognitive
decline, and mortality [34, 35].
Many features of an ageing immune system appear to be
driven by CMV, and infection with this virus has been linked
to poor vaccine responses in both young and elderly individ-
uals [36–39]. The eﬀects of CMV on the eﬀectiveness of vac-
cination remains a contentious issue, however, with some
studies showing no eﬀect in the elderly [38, 40, 41] and others
even showing vaccine-boosting eﬀects of CMV in young
individuals [42]. Irrespective of CMV serostatus, elderly indi-
viduals, exhibiting other established hallmarks of an ageing
immune system, generally mount less robust immune
responses to vaccines compared to young individuals [43].
Aside from inﬂuencing responses to novel antigens, CMV
infection has also been directly associated with frailty [44]
2 Oxidative Medicine and Cellular Longevity
and cognitive impairment [45], and some studies have shown
that infection results in earlier mortality [46–48].
3. Anti-Immunosenescence Effects of Exercise:
General Observations
The idea that aerobic exercise training could inﬂuence
immunosenescence developed in the late 1990s, almost two
decades after the ﬁeld of exercise immunology, was estab-
lished [49]. Many studies have investigated how the immune
system responds acutely (i.e., over minutes, hours, and days)
to diﬀerent modes, durations, and intensities of single and
repeated exercise bouts. Generally, exercise bouts are consid-
ered “immunostimulatory” partly due to the rapid exercise-
induced leukocytosis that was observed in early studies
[50–52]. Among lymphocytes, for example, and in particular
T cells and natural killer cells, subpopulations that exhibit
strong eﬀector function rapidly and substantially increase
in blood during exercise [1, 53, 54]. Subsequently, in the
hours following exercise, the same eﬀector cells migrate to
tissues, leaving blood to search for cells infected with viruses,
bacteria, or those that have undergone a malignant transfor-
mation [55, 56]. It is likely that these principles also translate
to other cells of the innate immune system, such as mono-
cytes and neutrophils, but these cells exhibit diﬀerent
exercise-induced kinetics compared to lymphocytes. Consid-
ering that these processes might reduce the risk of infections
[57] and facilitate the detection and elimination of tumours
[58], then these exercise-induced changes could be inter-
preted as countering some aspects of immunosenescence.
In addition to the short-term “immunostimulatory” eﬀects
of exercise bouts, long-term aerobic exercise training inter-
ventions, in both young and elderly individuals, elicit strong
anti-inﬂammatory eﬀects that might counter inﬂammageing
[6]. It seems that these exercise-induced eﬀects may not
have their roots in immune cells though and may be due
to other cytokine producing cells (e.g., myocytes, adipo-
cytes, ﬁbroblasts, endothelial, and epithelial cells) consider-
ing that long-term changes to the function and phenotype
of most immune cells are not brought about by regular
exercise training [6, 10].
Other studies have examined basal or resting immune
function in participants of cross-sectional or longitudinal
studies, categorising individuals as being sedentary, inactive,
physically active, or extremely active using self-report
questionnaires. A more recent approach has been objec-
tively measuring the volume and intensity of free-living
activities using wearable activity monitors. However, the
data generated by these devices is complicated to interpret
using globally recommended physical activity guidelines
(e.g., 150 minutes of moderate-to-vigorous intensity physical
activity each week on top of normal activities of daily living)
[59–61]. Wearable activity monitors capture activity accu-
mulated both purposefully (e.g., through exercise) and
through daily living, but because they do not discriminate
between the two, it has been suggested that a total of ~1000
minutes of moderate-to-vigorous intensity activity per week
is a more appropriate target to assess with these devices
[62]. Despite these important nuances, regularly active
individuals appear to exhibit better overall immune function
than inactive individuals, even in the elderly [10]. For exam-
ple, one of the most robust tests of immune competence is the
antibody or cell-mediated response to novel antigens, often
administered experimentally by vaccination. Both humoral
and cell-mediated responses to vaccination appear to be
stronger in active compared to inactive individuals and those
who have engaged in structured exercise in the months lead-
ing up to vaccine administration [5, 63]. Indeed, diﬀerent
forms of exercise appear to amplify vaccine responses, facili-
tating long-term immunity in the months after vaccination
[5, 63]. These eﬀects have been shown by studies that have
not controlled for the degree of immunological ageing
(e.g., stratifying by CMV serostatus) suggesting powerful
eﬀects of exercise.
Although many aspects of immune function change with
ageing, and some of these alterations can be bolstered or
restored transiently by diﬀerent forms of exercise, it remains
to be determined whether clinically meaningful and long-
term exercise-induced changes to the established hallmarks
of immunosenescence can be observed. However, evidence is
beginning to accumulate showing that some of these parame-
ters are at least sensitive to change by aerobic exercise training.
In addition, theories have been put forward for mechanisms
that might underlie possible anti-immunosenescence eﬀects
of exercise. So far, this work has largely focused on an ageing
adaptive immune system with an emphasis on T cells.
4. Anti-Immunosenescence Effects of Exercise:
Proposed Mechanisms
It has been suggested that aerobic exercise training might
prevent or delay immunological ageing by limiting the
expansion of senescent late-stage diﬀerentiated T cells, which
is a hallmark of immunosenescence [2, 3]. In this hypothesis,
it is proposed that three exercise-induced processes bring
about this eﬀect. First, cells of a late-stage diﬀerentiated phe-
notype are mobilised into peripheral blood during single
bouts of exercise. Second, these cells extravasate from blood,
homing to peripheral tissues, where they are exposed to proa-
poptotic stimuli (e.g., reactive oxygen species, glucocorti-
coids, and cytokines). Third, assuming that the “size” of the
adaptive immune system is ﬁxed, the naïve T cell repertoire
expands in response to the immunological “space” that has
been created, initiated by a hypothetical negative feedback
loop that governs the number of naïve and memory cells
and perhaps bolstered by exercise-induced thymopoiesis
and/or extrathymic T cell development in tissues such as
the liver.
Several parts of this hypothesis are supported by robust
ﬁndings in exercise immunology. For example, many investi-
gations have shown that late-stage diﬀerentiated T cells are
mobilised into peripheral blood during bouts of moderate-
and vigorous-intensity aerobic exercise, followed by an
assumed, in humans at least, extravasation to peripheral tis-
sues [53, 54]. In addition, there is evidence from studies in
mice that lymphocyte apoptosis occurs postexercise in tissues
that are thought to be the homing destination of mobilised
cells [64]. This process occurs in parallel with an increase of
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haematopoietic stem cells in the bloodstream and at these
homing sites, which seems to be an eﬀect of apoptotic cells
and cell debris [65]. Such apoptosis-induced haematopoietic
stem cell mobilisation might result in traﬃcking to the
thymus (or potentially extrathymic sites) stimulating the
development of naïve T cells [66]. Finally, contracting
skeletal muscle secretes IL-7 [67] which might increase
thymic mass and promote the emergence of recent thymic
emigrants [68]. Recent studies have provided insight into
whether the numbers and proportions of late-stage diﬀeren-
tiated T cells in peripheral blood are sensitive to change with
long-term exposure to aerobic exercise training. These
studies have been discussed in detail elsewhere [4] but
are summarised below.
5. The Effects of Aerobic Exercise Training on
Late-Stage Differentiated T Cells
There are no randomised and controlled trials that have
examined whether aerobic exercise training reduces the
numbers and proportions of late-stage diﬀerentiated T cells
resulting in clinically meaningful changes to overall immune
function. However, several cross-sectional studies have pro-
vided initial evidence that the characteristics of the T cell pool
vary between individuals who have been exposed to diﬀerent
volumes and intensities of aerobic exercise training over
periods of their life. In addition, limited evidence suggests
that the characteristics of the T cell pool are sensitive to mod-
ulation over several months when the volume and intensity
of aerobic exercise training are changed.
To summarise, it has been shown that individuals with a
high cardiorespiratory ﬁtness, which largely reﬂects an active
lifestyle, exhibit lower proportions of late-stage diﬀerentiated
T cells and higher proportions of naïve T cells in resting
blood samples [69]. The eﬀects of cardiorespiratory ﬁtness
appeared to be largely independent of age, body composition,
and CMV serostatus [69]. Similar observations have been
made in young adults who engage in structured exercise that
is typical of training for competitive team sports [70, 71].
In the elderly, however, an active lifestyle only appears
to limit the accumulation of late-stage diﬀerentiated T cells
and does not appear to substantially aﬀect the proportions of
naïve T cells [72]. Thus, these ﬁndings largely support an
anti-immunosenescence eﬀect of aerobic exercise training,
particularly in young adults. However, individuals undertak-
ing a much higher volume of endurance training appear to
exhibit exaggerated signs of T cell immunosenescence com-
pared to less active age-matched controls [73, 74]. Examples
of these changes include a greater accumulation of late-stage
diﬀerentiated T cells, fewer naïve T cells, and reduced thymic
output, as shown by lower levels of T cell receptor rearrange-
ment excision circles in resting blood samples [73, 74].
These eﬀects appear to be most prominent in younger
compared to older athletes [74]. Thus, these ﬁndings could
be interpreted as being a proimmunosenescence eﬀect of
very prolonged and repeated aerobic exercise bouts. In
support, it has been shown that over six months, when
very prolonged endurance training was undertaken by both
younger and older athletes, the numbers and proportions of
late-stage diﬀerentiated T cells increase and the numbers
and proportions of naïve T cells decrease [75, 76].
To conclude, it seems likely that individuals who meet or
exceed by less than approximately ﬁve times, the recommen-
dations for physical activity (i.e., accumulating 150 minutes
of moderate intensity or 75 minutes of vigorous-intensity
activity on a weekly basis) exhibit less marked immunosenes-
cence than age-matched controls who are not active [4].
However, individuals who take part in regular very pro-
longed or extreme aerobic exercise over their lifetime may
exhibit changes in the T cell pool that are indicative of exag-
gerated immunosenescence [4]. It seems that both the anti-
immunosenescence eﬀects of typical aerobic exercise training
and the proimmunosenescence eﬀects of extremely pro-
longed endurance training are most prominent in young
individuals. This indicates that the magnitude of eﬀect
brought about by aerobic exercise training is relatively mod-
est, or the eﬀects are at least masked within individuals who
already exhibit an aged immune proﬁle. Thus, the limited
evidence to date suggests that anti-immunosenescence eﬀects
of aerobic exercise training might have most utility in delay-
ing the onset of immunological ageing, rather than restoring
aged immune proﬁles. Although there is some evidence for
an anti-immunosenescence eﬀect of aerobic exercise training
on late-stage diﬀerentiated T cells, some concepts that
underlie the possible biological mechanisms are debated.
Indeed, many questions remain unanswered, such as how
many late-stage diﬀerentiated T cells truly classify as being
senescent, whether these cells can and should be removed,
and whether the “size” of the immune system is ﬁxed. These
themes are summarised below with a commentary on
whether some anti-immunosenescence eﬀects of aerobic
exercise training could be brought about indirectly.
6. What Are the Most Likely and Desirable
Anti-Immunosenescence Effects of Exercise?
A theme of the original idea for how aerobic exercise training
might counter immunosenescence has been the removal of
senescent late-stage diﬀerentiated T cells [2, 3]. This process
is considered desirable for two primary reasons: ﬁrst, because
it is thought some of these cells are unable to function
and second, because these senescent cells are thought to be
a waste of “space” assuming the “size” of the immune system
is ﬁxed.
The concept of a ﬁnite amount of immunological space
came about, in part, because it has traditionally been
assumed that thymic output of naïve T cells is negligible after
adolescence [14]. This implies that there is an upper limit to
the number of T cells in the immune system and a ﬁxed num-
ber of naïve cells capable of mounting responses to novel
antigens [14]. Thus, it has been proposed that antigen-naïve
cells could be “used up” due to ongoing diﬀerentiation into
memory cells that “ﬁll up” immunological “space” [14].
In addition, it has been suggested that the accumulation
of virus-speciﬁc T cells over a lifetime may lead to a
“squeezing out” of T cells targeting less dominant viruses
or nonpersistent infections, potentially leading to loss of viral
control [77]. Although studies continue to support the age-
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associated reduction in thymic output, evidence points
towards a gradual decline, whereby thymic function persists,
albeit reduced, up until around 70 years of age [78]. More-
over, the concept of a ﬁxed amount of immunological
space has been strongly debated [79, 80]. For example,
CMV-seronegative recipients of a CMV-infected kidney
demonstrate an “enlargement” of the CD8+ T cell compart-
ment, shown by an appearance and expansion of CMV-
speciﬁc T cells, but a maintenance (and not deletion) of pre-
existing Epstein Barr virus-speciﬁc and inﬂuenza-speciﬁc T
cells over time [79]. Although it remains up for debate if
there is a limit to the “size” of the immune system and
the number of naïve T cells within in it, the assumption
that low numbers of naïve cells increase the susceptibility
to infection has not been tested experimentally [8]. How-
ever, a removal of late-stage diﬀerentiated cells may be
desirable for other reasons, as for example, these cells
might contribute to the age-associated increase in inﬂam-
matory activity [14].
Assuming late-stage diﬀerentiated T cells remain func-
tional, it is likely that they have an important role in control-
ling latent viruses such as CMV. These cells, which do not
express CD27, CD28, CD62L, and CCR7, but express
CD45RA, CD57, and KLRG1 [7], almost exclusively accumu-
late due to CMV infection and reactivation and do not accu-
mulate in elderly CMV-seronegative individuals [7, 81, 82].
Thus, a targeted removal of these cells by exercise is probably
only relevant to individuals infected with CMV, but this is a
large proportion of the worldwide population (30–90%
depending on age, ethnicity, socioeconomic status, and geo-
graphical location) [83]. It is however well established that
in CMV-seropositive individuals, approximately 10% of the
CD4+ and CD8+ T cell pool becomes speciﬁc for this virus
[84]. Although such large accumulations of CMV-speciﬁc T
cells are often interpreted to be deleterious, it is unknown
what proportion of the T cell pool needs to be speciﬁc for
CMV to ensure adequate viral control [85]. The importance
of fully functioning late-stage diﬀerentiated T cells in con-
trolling latent viruses is highlighted by the complications that
arise from CMV reactivation and CMV disease in patients
receiving solid organ or stem cell transplants, which in part
is due to loss or suppression of cell-mediated immunity
[86]. Indeed, protocols have been developed to adoptively
transfer CMV-speciﬁc CD8+ T cells to prevent viral reactiva-
tion in transplant recipients [87]. Even in healthy individuals,
evidence points towards an important role for CMV-speciﬁc
immune surveillance. For example, in a longitudinal analysis
of elderly individuals, it has been shown that a lower propor-
tion of naïve CD8+ T cells, a higher proportion of memory
CD8+ T cells, combined with a robust proinﬂammatory
response to CMV, is associated with survival [88].
Along with uncertainty over how many CMV-speciﬁc
late-stage diﬀerentiated T cells are required for antiviral con-
trol, it is unclear what proportion of these cells classify as
being truly senescent. The assumption that many of these
cells are senescent came about because early studies showed
that the proportion of antigen-stimulated IFN-γ producing
cells among elderly donors was lower than in young donors
[89]. However, the cumulative IFN-γ production was higher
in the elderly due to greater absolute numbers of these
cells compared to the young [89], and this could therefore
be a mechanism to limit excessive inﬂammatory activity
when controlling CMV in the elderly. Most CMV-
speciﬁc cells are multifunctional, producing IFN-γ, IL-2,
and TNF-α, and have telomeres of intermediate length;
therefore, do not classify as senescent [90]. Although some
CMV-speciﬁc cells express programmed death-1 (PD-1),
this cell-surface protein is thought to better represent
exhausted cells that have impaired eﬀector function and
are not truly senescent [91, 92].
Although it might be desirable to remove truly senescent
late-stage diﬀerentiated T cells, it is likely that a biological
explanation exists for why these cells accumulate [14]. For
example, in vitro experiments have shown that senescent
CD8+ T cells, deﬁned as cells being incapable of cell division,
are resistant to apoptosis [93]. Conversely, other in vitro
work has shown that senescent T cells, deﬁned by expression
of cell-surface proteins that have been associated with senes-
cence such as CD57 and KLRG1, are more susceptible to
H2O2-induced apoptosis than naïve cells [94, 95]. When
examining CMV-speciﬁc CD8+ T cells in vitro, it has been
shown that rather than being resistant to apoptosis, these cells
are equally as susceptible to apoptosis as the broader pool of
CD8+ T cells [96]. However, in vivo experiments show that
peripheral blood CMV-speciﬁc CD8+ T cells exhibit high
levels of the antiapoptotic protein Bcl-2, potentially rendering
them insensitive to Fas-L/Fas-R-induced death [97]. Cur-
rently, it remains unclear whether CMV-speciﬁc late-stage
diﬀerentiated T cells, some of which may classify as being
senescent, are resistant to apoptosis in vivo.Thus, it is not cer-
tain if these cells would be susceptible to exercise-induced
apoptosis as part of countering an ageing immune system,
perhaps implicating other indirect mechanisms.
If aerobic exercise training invokes anti-
immunosenescence eﬀects by limiting the accumulation of
CMV-speciﬁc late-stage diﬀerentiated T cells, it could be that
these changes are brought about indirectly, by limiting viral
reactivation, improving redox balance, and countering
inﬂammageing. For example, many individuals who accu-
mulate large volumes of sedentary behaviour and do not
engage in physical activity are likely to be overweight or
obese, and it is possible that CMV will reactivate frequently
because adiposity drives chronic systemic inﬂammation
and oxidative stress [18, 98]. In turn, proinﬂammatory
cytokines and reactive oxygen species reactivate CMV
directly [99, 100]. Aerobic exercise training decreases visceral
and subcutaneous adipose tissue [101], providing a potent
anti-inﬂammatory stimulus that helps maintain redox bal-
ance [6, 102]. Exercise-induced improvements in redox
balance may also prevent dysfunction of late-stage diﬀer-
entiated T cells, considering that activation of the p38
mitogen-activated protein kinase signalling pathway by
excess reactive oxygen species prevents T cell proliferation
[103]. Thus, aerobic exercise training might delay the accu-
mulation of late-stage diﬀerentiated CMV-speciﬁc T cells
by reducing viral reactivation, or preventing T cell dysfunc-
tion, and by limiting adipose tissue accumulation and dys-
function that drives inﬂammation and oxidative stress.
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In support of the idea that sedentary behaviour and low
levels of physical activity might exacerbate immunosenes-
cence, perhaps via dysregulated adipose tissue, overweight
or obese individuals are at a greater risk of viral and bacterial
infections, have longer stays in hospital, and exhibit more fre-
quent and prolonged complications, such as antibiotic treat-
ment failure [104–106]. Further, obese individuals exhibit
diminished antibody responses to vaccination [107–109],
impaired lymphocyte proliferation to mitogens [110], and
shorter peripheral blood leukocyte telomere length [111]. In
addition, it has been shown that obesity is associated with
an accumulation of nTREGs and Th2-phenotype cells that
is also seen with ageing [112]. Other reports have shown that
obese individuals have large expansions of late-stage diﬀeren-
tiated αβ T cells and γδ T cells, with the latter exhibiting
impaired antiviral function [113–115]. Thus, aerobic exercise
training might counter immunosenescence indirectly by
limiting adipose tissue accumulation and dysfunction that
appear to exacerbate ageing processes.
In summary, the proposed anti-immunosenescence
eﬀects of aerobic exercise training that focus on limiting the
age-associated expansion of late-stage diﬀerentiated T cells
are desirable based on several assumptions. First, some of
these cells are classiﬁed as being senescent, failing to ade-
quately control latent viruses, but meanwhile contributing
to inﬂammageing. Second, the “size” of the immune system
is ﬁxed and the capacity to produce antigen-naïve T cells is
limited, and this process increases the risk of infections and
cancer in the elderly.
7. Immunosenescence and Cancer: An Overview
In 2015, there were 17.5 million cases of cancer worldwide
causing 8.7 million deaths, implicating malignancies as the
second most common cause of mortality behind cardiovas-
cular disease [116]. The incidence of cancer is increasing
worldwide, as shown by a 33% rise in cases between 2005
and 2015, largely driven by an ageing population [116]. This
age-associated increase in cancer incidence occurs in parallel
with the age-associated decline in immune function. How-
ever, the idea that immunosenescence causes or at least
increases susceptibility to cancer is controversial, even when
considering the observed relationships between immune
function and cancer risk or disease progression. For example,
there is a high incidence of cancer in people who are immu-
nosuppressed such as organ transplant recipients [117]. Sup-
porting the concept that a fully functioning immune system
hinders the development of cancer, a longitudinal study over
11 years, has shown that individuals with high natural killer
cell cytotoxicity, measured in cells isolated from peripheral
blood, exhibit a lower incidence of cancer than individuals
with less cytotoxic natural killer cells [118]. Indeed, clinical
reports of “spontaneous” cancer regression, “disappearance”
of tumours, and patients living with “dormant” cancer for up
to 20 years provide anecdotal evidence for the importance of
anticancer immunity [119]. However, strong evidence prov-
ing links between the age-associated decline in immune com-
petence and the development or progression of cancer is
lacking, despite advances in the scientiﬁc understanding of
tumour biology, the development of disciplines that focus
entirely on the immunology of cancer, and the subsequent
growth of cancer therapies that manipulate aspects of
immune function.
It is now almost universally accepted that the immune
system has a fundamental role in the detection and elimina-
tion of malignant cells, although some aspects of immune
function have also been linked to tumour progression
[117]. Indeed, the relationship between these processes and
malignancy is referred to as the cancer-immunity cycle
[120] and it is thought that when anticancer immune surveil-
lance becomes impaired, tumour masses become detectable
and clinically relevant [117, 121]. Subsequently, research
has led to extensive immunological characterisation of
tumours, with signature tumour-associated antigens estab-
lished and prioritised for the development of cutting-edge
treatments [122]. Even with conventional cancer therapies,
such as chemotherapy and radiotherapy, it is known that
the immune system facilitates some of their eﬀects [123].
Some recent cancer therapies stimulate aspects of immune
function, for example, by targeting immune check point
inhibitory circuits, and many treatments involve administer-
ing immune products such as cells, antibodies, or cytokines
[124–126]. Finally, some immunological variables predict
clinical outcomes in patients with cancer, such as tumour
inﬁltrating leukocytes ([127, 128] this extensive and complex
literature will not be discussed). Despite advances in our
understanding of the development, detection, and treatment
of malignancies, the quest to investigate whether causal or
correlational relationships exist between immunosenescence
and cancer is hampered by several unanswered and funda-
mental questions. First, do individuals who go on to develop
cancer already exhibit immunosenescent proﬁles, perhaps
due to low grade inﬂammation and chronic stimulation with
viral antigens? Second, does the development of cancer itself
cause immunosenescence, perhaps due to tumour-derived
inﬂammation and chronic stimulation with tumour-
associated antigens? Third, do processes involved in both
cancer and immunosenescence interact to exacerbate immu-
nological decline in patients with malignancies?
In principle, many characteristics of an ageing immune
system could contribute towards cancer risk and lead to poor
outcomes in patients. For example, chronic inﬂammation is
tumour promoting [13] and the age-associated changes to
the cellular composition and functional capability of the
immune system might impair the ability to detect and elimi-
nate cancer cells [11, 12, 129]. Candidate examples include
defects in the ability of innate immune cells to recognise
malignant transformation, such as reduced natural killer cell
cytotoxicity or defective toll-like receptor signalling in mac-
rophages and dendritic cells, with the latter exhibiting a
reduced ability to eﬀectively activate T cells [11, 12, 129].
Ineﬀective priming of T cells by dendritic cells may lead to
a weakened or anergic T cell response, which might be exac-
erbated by reduced thymic output of naïve T cells and an
accumulation of exhausted T cells that have been chronically
stimulated by virus or tumour antigens [11, 12, 129].
Thus, these eﬀects may limit the ability to respond to novel
antigens, such as those expressed by malignant cells. Age-
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associated reductions in less abundant T cell populations,
such as γδ T cells and CD1d-restricted iNKT cells, may also
impair cell-mediated tumour surveillance, and a decline in
the number and function of B cells may lead to a less eﬀective
antitumour humoral response [11, 12, 129]. Finally,
enhanced suppressive mechanisms with ageing may contrib-
ute, such as the accumulation of MDSCs, nTREGs, and Th2
cells producing suppressive or inhibitory cytokines such as
IL-10 and TGF-β [11, 12, 129]. Indeed, some of these inhib-
itory mechanisms may have their roots within tumour
masses, for example, as part of immune evasion strategies
adopted by malignant cells or the process of immunoediting,
whereby less immunogenic tumour cells are selected for and
subsequently persist [130]. Although it seems intuitive that
the age-associated decline in immune function could increase
cancer risk and hinder cancer therapy, the links between
malignancy and biomarkers of immunosenescence remain a
debated topic of research. Recent studies examining links
between immunosenescence and cancer are summarised in
the next section.
8. Do Immunosenescent Profiles Increase the
Risk of Cancer and Predict Poor Clinical
Outcomes in Patients with Malignancies?
If immunosenescence increases the risk of developing cancer,
then it might be expected for epidemiological studies to have
repeatedly shown relationships between markers of an ageing
immune system and the incidence of cancer or cancer-
speciﬁc mortality. Relationships of this kind are perhaps
diﬃcult to detect and interpret however. Only a few charac-
teristics of an ageing immune system have been linked to
all-cause mortality, and most studies have either not exam-
ined or have failed to detect associations with cancer-
speciﬁc deaths [31, 33–35, 46–48, 131]. Thus, it is unclear
whether classical biomarkers of immunosenescence can esti-
mate the chance of developing cancer or reﬂect the capacity
to detect and eliminate tumour cells. However, other mea-
surements of immune function that have not typically been
considered hallmarks of immunosenescence may provide
some insight. For example, a broad marker of immune com-
petence, salivary S-IgA, has been independently linked to
cancer. In a 19-year analysis of mortality data for 639 adults
aged 63 years at the time of measurement, there was a signif-
icant negative association between the secretion of S-IgA into
saliva and all-cause mortality, driven by an underlying asso-
ciation with cancer-speciﬁc mortality and in particular with
cancers other than lung cancer [132]. Importantly, these
relationships withstood adjustment for sex, occupation,
smoking, medication use, and self-reported health [132].
Although it is well established that the incidence of cancer
increases with age, coinciding with a decline in immune com-
petence, many other factors, including physical activity level,
body composition, and diet, which also change with ageing,
likely interact. Thus, even when predicting cancer risk with
accepted hallmarks of immunosenescence, such as plasma
inﬂammatory activity—a common parameter to have been
examined for associations with cancer, the results are likely
to be inﬂuenced by multiple lifestyle variables and infection
history, which have not always been assessed or controlled
robustly [133–135]. In the context of inﬂammation predict-
ing cancer risk, panels assessing multiple biomarkers may
have better predictive utility than individual inﬂammatory
variables, but the process of ageing and inﬂammageing is
highly variable between individuals and very closely related
to physical functioning [136]. The search for biomarkers that
predict cancer risk, cancer-speciﬁc mortality, and disease
progression in patients has spanned numerous immunologi-
cal, inﬂammatory, and genetic variables. It is beyond the
scope of this article to provide a thorough discussion of stud-
ies examining these general measurements of ageing. Thus,
the remainder of this section will summarise relationships
between cancer and the most established, robust, and
immunosenescence-speciﬁc biomarkers.
8.1. Infection with CMV and Risk of Developing Cancer.
Considering that many characteristics of an ageing
immune system are driven by infection with CMV, if
immunosenescence can be linked to cancer, it might be
expected that CMV-seropositive individuals would demon-
strate increased cancer-speciﬁc mortality. Links between
CMV and mortality are contentious, with some studies
reporting that CMV-seropositivity predicts greater all-cause
mortality [47, 131] and others showing no eﬀect of infection
[44, 137]. In addition, the investigations implicating CMV in
mortality mostly demonstrate that this relationship is driven
by death from cardiovascular disease rather than by cancer
[46, 48, 138]. However, in an analysis of 13,090 immunocom-
petent individuals aged 40–79 years at recruitment, which
showed CMV-seropositivity was associated with increased
all-cause mortality over a period of approximately 14 years
(age- and sex-adjusted hazard ratio 1.16), cause speciﬁc
analyses showed that in addition to cardiovascular disease
(hazard ratio 1.06), cancer also contributed to the overall
associations (hazard ratio 1.13) [139].
A small body of research has attempted to ﬁrmly estab-
lish links between CMV infection and the risk of developing
speciﬁc forms of cancer in healthy people. For example, it has
been hypothesised that late or recent exposure to CMVmight
cause breast cancer [140]. This idea was formed on the basis
that breast cancer incidence is higher in countries where
exposure to CMV occurs later in life, compared to countries
where almost the whole population is exposed during child-
hood [140]. In testing this hypothesis however, there were
no diﬀerences in CMV serostatus between women who
developed breast cancer compared to controls [141]. Yet, in
CMV-seropositive women, CMV-speciﬁc IgG was higher
among breast cancer patients compared to controls, which
was interpreted as reﬂecting recent exposure to CMV [141].
Similarly, it has been shown in CMV-seropositive women
that an increase in CMV-speciﬁc IgG, measured in serum
samples collected at least one year apart and approxi-
mately four years prior to breast cancer diagnosis, appears
to precede tumour development [142]. However, high or
rising CMV-speciﬁc IgG could also represent prolonged
infection due to exposure early in life, viral reactivation, or
superinfection with multiple virus strains [143, 144]. Indeed,
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associations between the sero-epidemiology of CMV infec-
tion and breast cancer incidence are not consistent with
measurements of viral DNA in breast tumours [145].
Other literature examining whether CMV increases the
risk of cancer has focussed on mortality after organ trans-
plantation. For example, it has been shown in a large study
of 22,461 recipients of kidney, heart, liver, or lung transplants
that mortality over 10 years, from a variety of causes, was
greater when organs from a CMV-seropositive donor were
transplanted into a CMV-seronegative recipient [146]. A
greater incidence of posttransplantation cancer was observed
among CMV-seropositive recipients compared to CMV-
seronegative recipients (irrespective of donor CMV seros-
tatus) [146]. Importantly, these associations were lost
when controlling statistically for age and sex, challenging
the links between CMV infection and cancer risk [146].
Other smaller studies have reported conﬂicting results.
For example, in a study of 455 kidney transplant recipi-
ents, it was shown that pretransplant exposure to CMV
and posttransplant CMV replication was associated with
an increased incidence of cancer [147]. Compared to
organ recipients who remained disease free, those who
developed cancer also exhibited other signs of immunose-
nescence, such as large expansions of CD8+CD28− T cells
[147]. In contrast, a study of 105 kidney transplant recip-
ients showed that CMV-naïve individuals, compared to
recipients who were exposed to CMV pre- or posttrans-
plant, demonstrated a greater risk of cancer, which was
attributed to antitumour activities of γδ T cells that accu-
mulate with CMV infection [148]. The relationships
between CMV infection and the risk of developing cancer
are unclear, and further research is required. However, it
may be that infection with this virus per se does not
increase the risk of developing cancer, and rather it is
the consequences of infection that are more important.
For example, in a study of 117 kidney transplant recipients
identiﬁed as being at high risk of cutaneous squamous cell
carcinoma, the age- or CMV-associated accumulation of
CD8+CD57+ T cells was a strong predictor of cancer
development, rather than viral infection directly [149].
8.2. Infection with CMV and Tumourigenesis. The majority
studies examining links between CMV and malignancy have
searched for viral DNA, RNA, and proteins in tumour cells
from individuals with a conﬁrmed cancer diagnosis or have
examined the eﬀects of infecting cancer cell lines with CMV
in vitro [150–152]. Most research implicates CMV in
tumourigenesis, rather than being a factor that increases the
risk of developing cancer, and a common view is that CMV
is “oncomodulatory,” infecting tumour cells and modulating
their malignant properties [150–152]. Changes include
increasing chromosome instability, stimulating proliferation
by dysregulation of the cell cycle, enhancing resistance to
apoptosis, facilitating invasion, migration and endothelial
adhesion, promoting angiogenesis, and contributing to
immune evasion [150–152].
The cancer diagnosis to have received most attention in
the context of CMV are malignant gliomas—the most com-
mon primary brain tumours in adults—comprising both
astrocytoma and glioblastoma multiform [152, 153]. It
was ﬁrst established in 2002 that a high percentage of
malignant glioma tumours are infected with CMV and
multiple gene products are expressed that likely contribute
to oncogenesis [154]. These ﬁndings have been conﬁrmed
by multiple studies [153]. It has also been shown that
there is a negative association between the number of
tumour cells infected with CMV and length of survival
[155]. In addition, treating glioma patients with Valganci-
clovir, which limits CMV reactivation, improves two-year
survival rate (by 72%) extending median survival by
approximately 43 months [156]. CMV has subsequently
been detected in tumour cells from patients with cervical
cancer [157, 158], breast cancer [145, 159], colorectal can-
cer [160], prostate cancer [161], and gastric cancer [162].
The speciﬁc role(s) that CMV might have in oncogenesis
and whether this virus negatively inﬂuences treatment out-
comes is uncertain for most of these cancers, and the
direction of eﬀect may even be surprising. For example,
despite the complications that CMV can have during the
treatment of haematological malignancies, CMV reactiva-
tion is associated with a decreased chance of cancer relapse
in acute myeloid leukaemia [163, 164].
8.3. Relationships between Cancer and Cellular Markers of
Immunosenescence. In addition to CMV infection, other hall-
marks of immunosenescence have been examined in patients
diagnosed with diﬀerent forms of cancer, and comparisons
have been made to healthy individuals, or relationships with
survival have been explored. For example, compared to
healthy controls, patients with glioblastoma multiform
exhibit lower percentages of total T cells, an accumulation of
γδ T cells, and expansions of αβ T cells with CD4+CD28−
and CD4+CD57+ phenotypes [165]. In addition, higher
levels of CD4+CD28− and CD4+CD57+ cells measured three
weeks after surgery in these patients were associated with
shorter survival [165]. Similar accumulations of CD28− and
CD57+ cells have been observed within the CD8+ T cell pool
in patients with lung cancer [166, 167]. These expansions of
CD8+CD28− cells were linked to broader aspects of immune
function and clinical outcomes, such as the eﬃcacy of a
therapeutic cancer vaccine, assessed by length of survival
following administration [167]. Other immune parameters,
such as the frequency of CD57+ NKT-like cells in gastric
cancer patients, have been reported as being comparable
to healthy controls [168]. However, among the most
advanced-stage patients, higher proportions of CD57+
NKT-like cells were associated with shorter survival [168].
Likewise, analysis of PD-1 expression on T cells from
patients with acute myeloid leukaemia revealed no diﬀer-
ences compared to healthy controls at the time of diagnosis,
but PD-1 expression increased substantially at the time of
relapse [169]. Thus, it seems that the timing of blood sam-
pling and stage of disease are critical for interpreting these
measurements. Other classical hallmarks of immunosenes-
cence have also been examined, with reports of low CD19+
B cell numbers in patients with lung cancer, along with a
decreased ratio of CD4+ T cells to CD8+ T cells, which
has also been shown in patients with late-stage melanoma
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[166, 167, 170]. These late-stage melanoma patients also
exhibited marked changes to the composition of the γδ
T cell pool, exhibiting a decline in the number of Vδ2 cells,
no change in Vδ1 cells, and a subsequent increase in the ratio
of Vδ1 to Vδ2 cells [170]. A higher frequency of Vδ1 cells was
negatively associated with survival, driven by Vδ1 cells with
an early diﬀerentiated phenotype (as with CD8+ early diﬀer-
entiated αβ T cells), but Vδ2 cells were not linked to clinical
outcomes [170].
It is possible that the alterations within the T cell
pool reported in patients with cancer are treatment- or
disease-induced acceleration of normal ageing processes,
such as reduced thymic output. For example, it has been
shown that patients with breast cancer, compared to
healthy controls, exhibit lower levels of T cell receptor
rearrangement excision circles and lower percentages of
recent thymic emigrants, observed in parallel with fewer
CD8+ naïve T cells and shorter telomeres assessed in
peripheral blood mononuclear cells [171]. Indeed, studies
have reported incremental changes to biomarkers of
immunosenescence following repeated administration of
chemotherapy, including lower ratios of CD4+ T cells to
CD8+ T cells and accumulations of CD28− and CD57+ cells
in patients with breast and lung cancer [166, 172]. Both
murine and human studies have shown that common che-
motherapeutic drugs induce a senescence-associated secre-
tory phenotype in peripheral blood T cells [173–175].
These so-called therapy-induced senescent cells, which accu-
mulate and contribute to local and systemic chronic inﬂam-
mation, can be identiﬁed by elevated expression of
p16INK4a, a tumour suppressor [173–175]. In T cells, p16INK4a
is a marker of molecular ageing in healthy individuals, and
its expression positively correlates with age and physical
inactivity [174, 176]. In patients with cancer, T cell
p16INK4a expression increases in a dose-dependent manner
with chemotherapy administration [174, 175]. Interest-
ingly, removal of p16INK4a expressing T cells increased
physical activity and strength in tumour bearing mice
[173]. Considering that in humans, p16INK4a T cell expres-
sion correlated with self-reported fatigue in the context of
breast cancer [173], and that exercise is recommended for
its fatigue-countering eﬀects [177, 178], then it might be
that some of the exercise-induced beneﬁts for patients
with cancer are, in part, brought about by interaction with
p16INK4a. Moreover, removal of p16INK4a expressing T cells
in mice has been shown to reduce cancer recurrence [173].
Thus, p16INK4a seems to be an important marker of T cell
senescence that not only interacts with exercise but might
also be linked with survival, perhaps due to better antican-
cer immunity. In support, it has been demonstrated that
IL-15 enhances the activity of tumour-speciﬁc T cells via
delaying or reversing senescence, as shown by lower
expression of p16INK4a among other markers of senescence
[179]. Indeed, recent research has indicated that the capac-
ity of peripheral blood T cells to recognise and respond to
tumour-associated antigens is a predictor of survival in
several malignancies, including breast cancer [180, 181],
colon cancer [182], melanoma [183, 184], and hepatocellu-
lar carcinoma [185].
9. Does Exercise Elicit Anticancer Effects by
Countering Immunosenescence?
9.1. Relationships between Active Lifestyles and Cancer: An
Overview. An active lifestyle reduces the risk of developing
cancer. In an analysis of self-report leisure-time physical
activity data from 661,137 people in six population-based
prospective cohorts, it was shown that the most active indi-
viduals (who performed more than ten times the recom-
mended minimum volume of exercise each week) had a
31% lower cancer mortality risk compared to individuals
reporting no activity [186]. Further, an investigation of risk
for diﬀerent cancer types among 1.44 million people from
twelve prospective studies showed, by comparing individuals
in the 90th and 10th percentiles for self-reported leisure-time
physical activity, that very active lifestyles are associated with
a lower risk of thirteen cancers, including oesophageal ade-
nocarcinoma, liver, lung, kidney, gastric cardia, endometrial,
myeloid leukaemia, myeloma, colon, head and neck, rectal,
bladder, and breast [187]. The reduction in risk ranged from
10 to 42% among the diﬀerent cancers, and most associations
remained signiﬁcant after statistical adjustment for body
mass index and smoking [187].
Despite substantial reductions in cancer risk brought
about by active lifestyles, the relevance and magnitude of
eﬀect for external and potentially modiﬁable factors inﬂuenc-
ing the development of malignancies has been debated. For
example, comparing the total number of tissue-speciﬁc life-
time stem cell divisions and the lifetime risk of cancer in
the same tissue has indicated that around 30% of the varia-
tion in cancer risk is due to external or inherited predisposi-
tions [188]. However, an alternative and more extensive
analysis of similar data proposed that external factors con-
tribute 70–90% of lifetime cancer risk [189]. A more conser-
vative estimate is provided by investigations of risk factor
exposure and cancer incidence. For example, approximately
43% of cancers occurring in the UK in 2010 have been attrib-
uted to suboptimal or past exposure to potentially modiﬁable
external factors [190]. Although the most substantial cancer
risk factor was tobacco, attributable to 19.4% of all diagnoses,
lifestyle factors that can in principle be modiﬁed by interven-
tion accounted for a substantial number of cases [190].
Factors included suboptimal diet (9.2%), overweight and
obesity (5.5%), consumption of alcohol (4.0%), and inade-
quate exercise (1.0%) [190]. Other exposures implicated in
the development of cancer, although potentially modiﬁable,
are more diﬃcult to avoid for practical, political, and societal
reasons (e.g., occupation 10.0%, ultraviolet radiation 3.5%,
ionizing radiation 1.8%, infections 3.1%, and reproductive
factors 0.9%) [190].
Although current evidence implicates inadequate physi-
cal activity as accounting for a modest proportion of cancer
diagnoses, these estimates are derived from self-reported
physical activity data and the relationships that had previ-
ously been established between speciﬁc cancers and active
lifestyles. Traditionally, research has linked inactive lifestyles
with risk of breast, colon, and prostate cancer, with some evi-
dence for endometrial and lung cancer [191]. However, more
recent research suggests that a much larger range of cancers
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are linked to inadequate physical activity, and it seems likely
that this list will grow as more data become available [187].
Thus, as new evidence accumulates using objective mea-
surements of physical activity in combination with mea-
surements of body composition that are more sensitive
than body mass index, the number of cancer cases attrib-
utable to inadequate physical activity may increase. Even if
with future research, the fraction of cancers thought to be
attributable to inactive lifestyles does not change; this esti-
mate should not be discounted. Preventing just 1% of the
17.5 million cases of cancer worldwide is attractive and
further justiﬁed by the increasing cancer incidence due to
an expanded ageing population [116].
It should be emphasised that the relationships between
cancer and exercise or physical activity are not limited to
reducing the risk of developing malignancies in healthy indi-
viduals. For example, there is a large body of evidence dem-
onstrating that aerobic exercise training can beneﬁt patients
with a cancer diagnosis. It is recommended that patients at
all stages of the cancer survivorship continuum (e.g., from
diagnosis, during and following treatment, to end of life)
adhere to the same physical activity guidelines as for healthy
individuals, so long as the mode, duration, intensity, and fre-
quency of each exercise session are appropriate for the stage
of disease and nature of treatment [177]. This recommenda-
tion has been made on the basis that exercise brings about
many beneﬁts for patients, including improvements in
overall quality of life, cardiorespiratory ﬁtness, strength,
ﬂexibility, mood, anxiety, and self-esteem [192, 193]. In
addition, aerobic exercise training is an eﬀective method
for countering some of the side-eﬀects of cancer treatment,
such as fatigue [178]. Most importantly, there are strong
relationships between cardiorespiratory ﬁtness or habitual
engagement in physical activity with positive treatment
outcomes, including reduced disease recurrence and longer
survival [192, 193]. These relationships have been demon-
strated by observational studies of patients with diﬀerent
malignancies, including breast, prostate, colorectal, and lung
cancer [194–198]. In support, the relationship between
survival and aerobic exercise training during cancer ther-
apy has been shown by a randomised and controlled trial
in patients with breast cancer [199].
9.2. Relationships between Active Lifestyles and Cancer:
Possible Mechanisms. The mechanisms underlying relation-
ships between regular engagement in physical activity and
the risk of developing cancer, some of which are also likely
to be relevant to the positive eﬀects that an active lifestyle
can have on clinical outcomes in patients, have not been con-
ﬁrmed. This is despite conceptual understanding of the natu-
ral mechanisms protecting against cancer, which can be
divided into two broad categories: ﬁrst, defences that reduce
or limit exposure to factors that promote malignant transfor-
mation and tumour growth and second, defences that target
malignant cells more directly [200]. The ﬁrst category of
defences might be considered nonimmune mechanisms and
include dietary anticarcinogenic substances, such as antioxi-
dant vitamins; enzymes that actively remove carcinogenic
substances, such as antioxidant enzymes; sensors of DNA
damage that trigger repair or apoptosis; tumour suppressor
genes; telomeres that limit cell division; and inhibitors of
angiogenesis, cell migration, or invasion [200]. The second
category of defences might be considered immune mecha-
nisms and comprise almost all aspects of humoral and cell-
mediated immunity, spanning the innate and adaptive
immune compartments [200]. Thus, active lifestyles or aero-
bic exercise training could conceivably elicit protective eﬀects
via interaction with several of these defences [201].
Many of the exercise-induced anticancer mechanisms
proposed in the literature have focussed on processes rele-
vant to the cancers traditionally linked with reduced risk
brought about by active lifestyles. For example, in the context
of colon cancer, it has been suggested that regular aerobic
exercise training or physical activity increases gastrointesti-
nal transit time, reducing mucosal exposure to potentially
carcinogenic substances [191]. With breast cancer, it has
been proposed that regular aerobic exercise training or phys-
ical activity reduces lifetime exposure to oestrogen, perhaps
due to delayed menarche and reduced ovulatory cycles
[191]. Finally, the traditionally observed lower risk of pros-
tate cancer has been attributed to an exercise-induced pro-
duction of sex hormone binding globulin that reduces
exposure to testosterone [191]. Other more widely applicable
and commonly proposed anticancer eﬀects of regular aerobic
exercise training or physical activity include reducing oxida-
tive stress and inﬂammation, limiting adipose tissue accumu-
lation, modulating the insulin-like growth factor axis, and
stimulating immune function [201, 202]. Most research has
sought to identify mechanisms that could explain the lower
incidence of cancer in very active individuals. However, lim-
ited research has investigated mechanisms underlying better
clinical outcomes exhibited by patients who remain regularly
active or engaged in structured aerobic exercise training
during cancer treatment. For example, a murine model
of breast cancer showed that regular wheel running
improved the eﬀectiveness of chemotherapy by promoting
tumour vascularity, reducing tumour hypoxia, and subse-
quently enhancing tumour perfusion [203]. A factor that
is likely to be relevant to both reducing the risk of devel-
oping cancer in healthy individuals, but also improving
treatment outcomes in patients, is an exercise-induced
enhancement of immune surveillance that might facilitate
the detection and elimination of malignant cells. Research
exploring this idea has so far focussed on natural killer
cells. For example, in humans, it has been shown that an
acute bout of vigorous-intensity exercise mobilises highly
cytotoxic natural killer cells improving their ability to lyse
multiple myeloma and lymphoma cell lines [204]. In addi-
tion, murine models of melanoma, lung, and liver cancer
have shown that repeated bouts of wheel running stimulate
an adrenaline- and IL-6-dependent mobilisation of natural
killer cells into peripheral blood, which subsequently extrav-
asate and home to implanted tumours, limiting cancer
growth [58]. Indeed, it is likely that research investigating
exercise, muscle, tumour, and immune cross-talk, exploring
a role for both cellular and soluble mediators, will bring
further insights into the most likely anticancer eﬀects of
aerobic exercise training [205].
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9.3. Relationships between Active Lifestyles and Cancer: An
Anti-Immunosenescence Eﬀect of Exercise? Considering that,
ﬁrst, physical activity reduces the risk of developing cancer,
second, cancer risk might be modulated by immunosenes-
cence, and third, aerobic exercise training may bring about
anti-immunosenescence eﬀects, it has never been investi-
gated whether the anticancer properties of exercise are elic-
ited by countering immunological ageing. To emphasise, as
healthy individuals who undertake a moderate volume of
aerobic exercise throughout their lifetime appear to have a
reduced risk of developing cancer and may exhibit less
marked immunosenescence than those who are inactive, it
could be hypothesised that these two observations are linked.
In other words, does aerobic exercise training reduce the risk
of developing cancer by limiting the age- and infection-
associated accumulation of late-stage diﬀerentiated T cells
along with concomitant changes in the naïve T cell pool,
and perhaps overall immune function? Although worthy of
investigation, this hypothesis may not be conﬁrmed. First,
in healthy individuals who are not immunosuppressed, the
characteristics of the T cell pool have not been directly and
robustly linked to the development of cancer. Second,
although individuals undertaking extremely large volumes
of endurance exercise may exhibit exaggerated signs of
immunosenescence, there is generally a dose-response rela-
tionship between exercise and all-cause mortality and
cancer-speciﬁc mortality [186, 187]. Despite the exception
of links between ultraendurance exercise and cardiovascu-
lar risk [206], engagement in very high-volume exercise
has not been linked with morbidity and mortality from
other diseases, especially cancer [186, 187]. However, anti-
immunosenescence eﬀects of aerobic exercise training might
have more relevance for patients who have been diagnosed
with cancer and are undergoing treatment. As outlined
earlier, higher cardiorespiratory ﬁtness and regular exercise
is linked to successful cancer treatment and longer survival
[192–199]. In addition, exacerbated immunological decline,
assessed by measuring cellular markers of immunosenes-
cence, is linked to unsuccessful cancer treatment and shorter
survival [165–168, 170]. Thus, it is possible that positive
treatment outcomes, exhibited by patients with high cardio-
respiratory ﬁtness, who are physically active or undertake
regular aerobic exercise training and exhibit less marked
immunosenescent proﬁles compared to their inactive coun-
terparts, could be driven by an anti-immunosenescence eﬀect
of exercise.
10. Conclusions
Considering that ageing results in impairments to innate and
adaptive immunity and that a single bout of exercise is
a powerful stimulus of immune function, it is appealing
that regular aerobic exercise training might exert anti-
immunosenescence eﬀects. Evidence is accumulating in
support of this idea, and these exercise-induced eﬀects might
delay the age-associated alterations to immune function.
Although it is unknown whether such eﬀects are brought
about by exercise directly, such as a targeted removal of dys-
functional T cells, or indirectly, such as lower inﬂammatory
activity and less frequent viral reactivation, it is conceivable
that these changes will bring about considerable beneﬁts to
health, including reduced morbidity and mortality from
infectious disease and cancer.
The links between biomarkers of immunosenescence and
the risk of developing cancer in healthy individuals remain to
be fully established. However, evidence is beginning to show
that patients diagnosed with cancer exhibit immunosenes-
cent proﬁles. Analysis of disease outcomes, in combination
with measurements estimating the extent of immunosenes-
cence, suggests that exacerbated immunological ageing is
linked to unsuccessful clinical outcomes in several cancers.
Considering that active lifestyles reduce the risk of develop-
ing cancer and are associated with positive treatment out-
comes in patients, it is possible that some of these eﬀects
could be driven by an anti-immunosenescence eﬀect of regu-
lar aerobic exercise training.
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